Identity and synonyms
FOXO4 without DRI is an unresolved listing; do not infer D-retro-inverso identity.
Peptide or peptide-related · Identity or class unresolved
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Commercial identity or variant awaiting clarification.
Mechanism
FOXO4 is a transcription factor; the name alone does not identify a specific-sequence senolytic peptide.
Evidence and critical reading
Reported scientific and empirical uses
Aging research
Keep separate from FOXO4-DRI until commercial material is confirmed to match the investigated retro-inverso variant.
Human evidence
FOXO4-DRI cell/animal experiments do not justify attributing activity, dose or safety to any vial called FOXO4.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
FOXO4-DRI cell/animal experiments do not justify attributing activity, dose or safety to any vial called FOXO4.
FOXO4-DRI cell/animal experiments do not justify attributing activity, dose or safety to any vial called FOXO4.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No human regimen was verified for this identity. Removing senescent cells is an intervention hypothesis, not safe rejuvenation.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
FOXO4 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID28340339
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ.
October 16, 2026
- SEARCH-PUBMED-foxo4-unspecified
PubMed/MED targeted search: TITLE_ABS:FOXO4 AND TITLE_ABS:peptide AND TITLE_ABS:human
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026